

SUPPLEMENTARY TABLES

Supplementary Table 1. The sensitivity of parental cell lines (HCT116, HCT8) and 5FU-resistant cell lines (HCT116/FU, HCT8/FU) to anticancer drugs.

Drug	HCT116 IC50* (µg/ml)	HCT8 IC50* (µg /ml)	HCT116/FU IC50* (µg /ml)	HCT8/FU IC50* (µg /ml)
5- Fluorouracil	22.88 ± 0.14	25.59 ± 0.16	146.14 ± 15.06	140.22 ± 10.40
Irinotecan	41.26 ± 2.82	43.17 ± 1.11	259.40 ± 2.43	267.03 ± 1.56
Capecitabine	9.10 ± 0.22	8.44 ± 1.01	98.01 ± 5.89	102.00 ± 3.23
Oxaliplatin	6.60 ± 1.10	8.00 ± 1.99	32.07 ± 7.58	33.62 ± 3.02

IC50*, The IC50 values were defined as the concentration of cells inhibiting growth at 50%.

Supplementary Table 2. Sequences for primers used in this study.

Name	Sequence
q-PCR primers	
has-mir-375-3p-F	CTTACTATCCGTTTGTTCGTTTCG
has-mir-375-3p-R	TATGGTTGTTCTCGTCTCTGTGTCT
U6-F	CAGCACATATACTAAAATTGGAACG
U6-R	ACGAATTTGCGTGTCATCC
YAP1-F	TAGCCCTGCGTAGCCAGTTA
YAP1-R	TCATGCTTAGTCCACTGTCTGT
SP1-F	TGGCAGCAGTACCAATGGC
SP1-R	CCAGGTAGTCCTGTCAGAACTT
PRKD1-F	TTCTCCCACCTCAGGTCATC
PRKD1-R	TGCCAGAGCACATAACGAAG
HAS2-F	GCCTCATCTGTGGAGATGGT
HAS2-R	ATGCACTGAACACACCCAAA
ELK4-F	CTGGTGCCAAGACCTCTAGC
ELK4-R	TCGGCTGGATTCTCAGTCTT
HOXA3-F	TCATTTAAGAGCGCCTGGACA
HOXA3-R	GAGCTGTCGTAGTAGGTGCGC
ACSL3-F	TGCTTTCCGAAGCTGCTATT
ACSL3-R	AAGGCATCTGTCACCAGACC
MXI1-F	TGGCTACGCCTCTTCATCC
MXI1-R	CTGTTGGCAGTGCTGGTGT
UBE3A-F	CCATGGGAAAATGTACATCCA
UBE3A-R	TTTTTCAGCTGGTTGTGGAGG
JUND-F	TCAAGACCCTCAAAGCCAGAA
JUND-R	TTGACGTGGCTGAGGACTTTC
TCF12-F	GCTCGACGCTAGGATCTGAC
TCF12-R	GCTTTCCACGACGGTGAC
PDE4D-F	AGGGTCTGGGCTGATTCTC
PDE4D-R	GTTGATGGATGGTTGGTTGC
KLF4-F	AAGCCAAAGAGG GGAAGACG
KLF4-R	GTGCCTGGTCAGTTCATCTGAG
GAPDH-F	GAAGGTGAAGGTCGGAGTC
GAPDH-R	GAAGATGGTGATGGGATTTC

Supplementary Table 3. Sequences for siRNAs used in this study.

Name	Sequence
siRNAs	
siYAP1 # 1(sense)	GGUGAUACUAUCAACCAAA
siYAP1# 1(antisense)	CCACUAUGAUAGUUGGUUU
siYAP1 # 2(sense)	GAUGUCUCAGGAAUUGAGA
siYAP1# 2(antisense)	CUACAGAGUCCUUAACUCU
siYAP1 # 3(sense)	AACUCGGCUUCAGGUCCUC
siYAP1# 3(antisense)	UUGAGCCGAAGUCCAGGAG
siSP1# 1(sense)	CCUGGAGUGAUGCCUAAUATT
siSP1# 1(antisense)	UAUUAGGCAUCACUCCAGGTT
siSP1# 2(sense)	GUGCAAACCAACAGAUUAUTT
siSP1# 2(antisense)	AUAAUCUGUUGGUUUGCACTT

Supplementary Table 4. Antibodies information in this study.

		Western blot	IHC
YAP1 Rabbit Polyclonal Antibody	Proteintech#13584-1-AP	1:5000-1:50000	1:50-1:500
SP1(D4C3) Rabbit mAb	Cell Signaling Technology#9389	1:1000	1:2000
Ki67 Rabbit Polyclonal antibody	Proteintech #27309-1-AP		1:4000
Caspase 3 Rabbit Polyclonal antibody	Proteintech#19677-1-AP	1:500-1:1000	
PARP1 Rabbit Polyclonal antibody	Proteintech#13371-1-AP	1:500-1:2000	
BCL2 Rabbit Polyclonal antibody	Proteintech#12789-1-AP	1:1000-1:4000	
Cyclin D1 Mouse Monoclonal antibody	Proteintech#60186-1-Ig	1:2000-1:10000	
CTGF Rabbit Polyclonal antibody	Proteintech#23936-1-AP	1:500-1:1000	
SURVIVIN(BIRC5) Rabbit Polyclonal antibody	Proteintech#10508-1-AP	1:500-1:2000	
HRP-conjugated GAPDH Mouse Monoclonal antibody	Proteintech#HRP-60004	1:5000-1:50000	
GAPDH Rabbit Polyclonal antibody	Proteintech#10494-1-AP	1:10000-1:40000	
Goat Anti-Mouse IgG antibody	Bioss#bs-0296G	1:5000	
Goat Anti-rabbit IgG antibody	Bioss#bs-0295G	1:5000	

Supplementary Table 5. Clinical characteristics of CRC patients who received 5FU-based chemotherapeutic treatment.

Patient(S*/R*)	Age	Gender(F*/M*)	Pathological diagnosis	TNM	Weeks of treatment
S1	54	F	CRC	T ₃ N ₁ M ₁	24
S2	52	M	CRC	T ₂ N ₂ M ₀	21
S3	36	F	CRC	T ₂ N ₀ M ₀	24
S4	36	M	CRC	T ₃ N ₁ M ₀	16
S5	58	M	CRC	T ₃ N ₁ M ₀	22
S6	63	F	CRC	T ₂ N ₁ M ₀	15
S7	51	M	CRC	T ₃ N ₂ M ₀	16
S8	71	F	CRC	T ₃ N ₁ M ₀	16
S9	42	M	CRC	T ₂ N ₀ M ₀	19
S10	34	F	CRC	T ₂ N ₂ M ₀	22
S11	39	F	CRC	T ₃ N ₁ M ₀	21
S12	67	F	CRC	T ₃ N ₁ M ₁	15
S13	49	M	CRC	T ₃ N ₁ M ₀	12
S14	59	F	CRC	T ₂ N ₁ M ₀	23
S15	44	F	CRC	T ₂ N ₁ M ₀	21
S16	47	M	CRC	T ₃ N ₀ M ₀	13
S17	56	M	CRC	T ₁ N ₀ M ₀	13
S18	48	F	CRC	T ₃ N ₁ M ₀	21
S19	63	M	CRC	T ₂ N ₁ M ₀	18
S20	72	F	CRC	T ₁ N ₀ M ₀	21
S21	47	F	CRC	T ₃ N ₁ M ₁	21
S22	31	F	CRC	T ₄ N ₁ M ₀	18
S23	47	M	CRC	T ₂ N ₀ M ₀	21
S24	40	M	CRC	T ₃ N ₀ M ₀	24
S25	43	F	CRC	T ₄ N ₀ M ₀	20
S26	58	M	CRC	T ₂ N ₁ M ₀	21
S27	72	M	CRC	T ₂ N ₁ M ₀	21
S28	49	F	CRC	T ₄ N ₁ M ₀	24
S29	39	F	CRC	T ₃ N ₁ M ₀	11
S30	51	M	CRC	T ₃ N ₂ M ₀	16
R1	63	M	CRC	T ₂ N ₀ M ₀	20
R2	46	M	CRC	T ₁ N ₁ M ₀	21
R3	39	F	CRC	T ₄ N ₀ M ₀	15
R4	58	M	CRC	T ₄ N ₁ M ₁	16
R5	57	M	CRC	T ₂ N ₂ M ₀	24
R6	47	M	CRC	T ₂ N ₁ M ₀	15
R7	45	F	CRC	T ₃ N ₀ M ₀	21
R8	28	F	CRC	T ₂ N ₀ M ₁	21
R9	37	M	CRC	T ₃ N ₁ M ₀	21

R10	46	F	CRC	T ₃ N ₀ M ₀	18
R11	57	F	CRC	T ₄ N ₀ M ₀	24
R12	55	M	CRC	T ₃ N ₁ M ₀	24
R13	37	F	CRC	T ₄ N ₂ M ₁	24
R14	49	M	CRC	T ₃ N ₀ M ₀	21
R15	51	M	CRC	T ₂ N ₂ M ₀	24
R16	47	F	CRC	T ₄ N ₂ M ₁	21
R17	68	M	CRC	T ₃ N ₁ M ₀	21
R18	61	F	CRC	T ₂ N ₁ M ₁	15
R19	59	M	CRC	T ₃ N ₂ M ₀	27
R20	55	M	CRC	T ₂ N ₁ M ₀	22
R21	50	M	CRC	T ₂ N ₁ M ₀	21
R22	63	M	CRC	T ₂ N ₀ M ₀	18
R23	46	M	CRC	T ₁ N ₁ M ₀	17
R24	39	F	CRC	T ₄ N ₀ M ₀	21
R25	58	M	CRC	T ₄ N ₁ M ₁	21
R26	57	M	CRC	T ₂ N ₂ M ₀	21
R27	66	F	CRC	T ₃ N ₂ M ₀	22
R28	72	M	CRC	T ₃ N ₂ M ₀	21
R29	68	F	CRC	T ₃ N ₁ M ₀	21
R30	59	F	CRC	T ₂ N ₁ M ₁	24

S*, Sensitivity, 5FU-sensitive. Patients who responded well to 5FU-based chemotherapeutic treatment;

R*, Relapse, 5FU-resistant. Patients who relapsed after the first 5FU-based chemotherapeutic treatment.

F*, Female. **M***, Male.